1. Home
  2. YMAT vs NXL Comparison

YMAT vs NXL Comparison

Compare YMAT & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo J-Star Holding Co. Ltd. Ordinary Shares

YMAT

J-Star Holding Co. Ltd. Ordinary Shares

HOLD

Current Price

$1.82

Market Cap

7.3M

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.62

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YMAT
NXL
Founded
1970
2010
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
7.5M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
YMAT
NXL
Price
$1.82
$0.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.6K
138.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.76
EPS
N/A
N/A
Revenue
N/A
$301,647.00
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
78.78
52 Week Low
$0.24
$0.31
52 Week High
$2.94
$2.00

Technical Indicators

Market Signals
Indicator
YMAT
NXL
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
YMAT
NXL

About YMAT J-Star Holding Co. Ltd. Ordinary Shares

J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Share on Social Networks: